🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-523229-16-00
Ongoing Phase II

A Phase 2 controlled randomized study of the efficacy of L19IL2 or L19TNF or L19IL2/L19TNF intralesional injections for the treatment of locally advanced basal cell carcinoma patients.

2025-523229-16-00 · tracked via the Priya Life Science EU tracker
Sponsor
Philogen S.p.A.
Sponsor type
Pharmaceutical company
Therapeutic area
Skin and Connective Tissue Diseases
Decision date
10/02/2026
Enrollment target
85
Sites
Greece, Italy, Germany, Spain

Condition studied

locally advanced basal cell carcinoma patients

Investigational medicinal product(s)

FibromunDarleukin

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male

Primary endpoint

The primary objective of the study is to evaluate the efficacy of L19IL2 or L19TNF or L19IL2/L19TNF.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523229-16-00 on CTIS ↗ ← All trials in the EU